CDC advises healthcare providers on new tools to combat RSV

In a latest public health advisory, the USA Facilities for Illness Management and Prevention (CDC) predicts the respiratory syncytial virus (RSV) exercise for the upcoming winter season and encourages clinicians to undertake and implement new RSV prevention instruments. 

Advisory: Increased Respiratory Syncytial Virus (RSV) Activity in Parts of the Southeastern United States: New Prevention Tools Available to Protect Patients, Distributed via the CDC Health Alert Network, September 05, 2023, 2:00 PM ET CDCHAN-00498. Picture Credit score: Pete Hansen / Shutterstock.com

Background

Yearly, the CDC points a well being advisory for the general public and clinicians all through the USA via its Well being Alert Community (HAN) concerning RSV exercise. RSV, a ribonucleic acid (RNA) virus, causes extreme respiratory infections in infants, kids, and older adults.

Previous to the coronavirus illness 2019 (COVID-19) pandemic, the annual RSV season within the U.S. started within the fall and infrequently reached its peak by winter. Because of mitigation measures applied through the pandemic, RSV unfold lowered between Might 2020 and March 2021; nevertheless, the unfold of RSV ultimately returned to its typical seasonal pattern. 

Nonetheless, in 2021, RSV started spreading in Might, peaked by August, and continued via December. In 2022, RSV once more grew to become energetic in the summertime however peaked in October and November, declining quickly by winter. 

Not like its onset timing, post-pandemic RSV exercise follows the identical geographic sample as earlier than the pandemic in 2021-2022. Extra particularly, RSV usually begins to unfold in Florida, shifting all through the southeast after which spreading additional to the northern and western U.S.

In 2023, the CDC noticed elevated RSV exercise within the southeastern U.S. in late August. In accordance with the Nationwide Respiratory and Enteric Virus Surveillance System (NREVSS) knowledge, the weekly share of polymerase chain response (PCR) test-based optimistic detections remained beneath the season’s onset threshold of three% for 2 weeks. 

In Georgia, charges of RSV-associated hospitalizations elevated, whereas in Florida, the three-week PCR positivity shifting common was over 5% from the week ending July 22, 2023. 

New instruments for RSV prevention

In 2023, nirsevimab, in addition to RSVPreF3 and RSVpreF vaccines, grew to become out there to the general public since their latest approval. Nirsevimab is a U.S. Meals and Drug Administration (FDA) authorized long-acting monoclonal antibody (mAb) that’s at present indicated for infants youthful than eight months, in addition to kids between eight to 19 months of age who’re at a excessive threat of extreme sickness as a result of RSV an infection. Medical trials have established {that a} single intramuscular injection of nirsevimab is protected, efficient, and will shield infants for not less than 5 months.

The CDC requested clinicians to seek the advice of native, territorial, or state authorities on the timing of nirsevimab use, particularly in areas with much less predictable RSV seasonality. Present suggestions for nirsevimab embrace one dose for all infants ages eight months or youthful getting into their first RSV season or born throughout this time, inside the first week of start, and one other as early as potential throughout their first RSV season. The prescribed dose is 50 and 100 mg for infants weighing lower than 5 kilograms (kg) and over 5] kg, respectively. 

The CDC additionally recommends that kids between eight and 19 months of age who’re at an elevated threat of RSV an infection, resembling those that are immunocompromised, ought to obtain one dose of 200 mg nirsevimab earlier than getting into their second RSV season. 

In accordance with the American Academy of Pediatrics (AAP) suggestions, kids 24 months or youthful at a better threat for extreme RSV illness might additionally obtain palivizumab mAb till nirsevimab turns into out there.

RSVPreF3 and RSVpreF, that are recombinant protein vaccines, have additionally obtained FDA approval to be used in adults 60 years and older. In a medical trial that included 38,177 members over 60 years of age, these vaccines had been related to over 80% efficacy in stopping RSV-related decrease respiratory tract illness. The RSVpreF vaccine was additionally authorized to be used in pregnant ladies between 32-36 weeks.

Clinicians are suggested to debate RSV vaccination with their grownup sufferers who’re over 60 years of age. Notably, all vaccines for which a affected person is eligible, together with these towards COVID-19, influenza, and RSV, could also be administered collectively.

Adults with superior age and particular persistent medical situations, resembling persistent obstructive pulmonary illness (COPD), may profit probably the most from vaccination. Clinicians also needs to take into account testing symptomatic sufferers to tell affected person administration and ask these testing optimistic to remain dwelling to stop onward viral transmission.

Conclusions

RSV causes between 58,000-80,000 and 60,000-160,000 hospitalizations in kids 5 years and youthful and adults aged 65 years and older, respectively, yearly within the U.S.

Given its elevated exercise within the southeastern U.S. in August 2023, healthcare service suppliers should stay ready and knowledgeable and take preventive measures to cut back the chance of RSV-related hospitalizations and demise.